<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01604213</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-12-9455-RK-CTIL</org_study_id>
    <nct_id>NCT01604213</nct_id>
  </id_info>
  <brief_title>Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease</brief_title>
  <acronym>VAAST</acronym>
  <official_title>Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that combined vildagliptin-metformin therapy is
      associated with clinically significant reductions in biological markers of inflammation,
      pro-thrombogenicity, and atherosclerosis as compared to metformin mono-therapy in a
      population of diabetic patients with coronary artery disease who undergo cardiac
      rehabilitation.

      The pre-specified established biological markers of inflammation, pro-thrombogenicity, and
      atherosclerosis will include: interleukin-6 (IL-6 - primary biological marker), hs-CRP,
      platelet reactivity testing, MMP-9, Interleukin 1 beta (IL-1 beta) and adiponectin levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a single-center, randomized, non-blinded, clinical trial to provide
      evidence on the effects of vildagliptin on key biomarkers of atherothrombosis and
      inflammation. We plan to prospectively enroll 60 patients with proven coronary artery disease
      and randomize them in a 2:1 ratio to either vildagliptin-metformin therapy (n=40) or
      metformin therapy (n=20).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in serum levels of Interleukin 6 (IL-6)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in other markers of athero-thrombosis and inflammation:</measure>
    <time_frame>3 months</time_frame>
    <description>I. Improvement in other markers of athero-thrombosis and inflammation:
High sensitivity C-reactive protein (hs-CRP),
Platelet reactivity
Adiponectin levels
IL-1 beta
Matrix metallo-peptidase 9 (MMP-9)
Additional exploratory markers including: IL-1 alpha ,, IL-17, TNF-alpha, MCP-1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Vildagliptin+metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Vildagliptin+metformin combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral metformin only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus vildagliptin</intervention_name>
    <description>Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary</description>
    <arm_group_label>Vildagliptin+metformin</arm_group_label>
    <other_name>Eucreas</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin only</intervention_name>
    <description>Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated</description>
    <arm_group_label>Metformin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus on oral mono-therapy or diet only treatment

          -  Stable documented ischemic Heart disease (&gt;30 days post AMI, CABG or PCI)

          -  Sub-optimal Hb A1c as defined ≥6.5%

          -  Age &gt; 21

          -  Life expectancy &gt;1 year

        Exclusion Criteria:

          -  Significant renal impairment (creatinine ≥1.4 mg\dL females or ≥1.5 mg\dL males)

          -  Planned coronary intervention or planed surgical intervention (PCI or CABG)

          -  Planned surgical intervention

          -  Recent (&lt;30 day) acute coronary syndrome (ACS)

          -  Hypersensitivity to either of the study drug components

          -  History of lactic acidosis

          -  Type I diabetes

          -  Current Hb A1c &gt;9%

          -  Current Insulin treatment

          -  Active treatment with GLP-1 or DPP4i medication

          -  Hepatic impairment or ALT\AST elevations beyond X2 upper normal limit or known hepatic
             failure

          -  Inability to comply with study protocol

          -  Active malignancy other than basal cell carcinoma (BCC)

          -  Clinically advanced congestive heart failure - NYHA III-IV

          -  Severe left ventricular dysfunction (LVEF&lt;30%) with NYHA II or any NYHA class with
             documented recent heart failure decompensation (&lt;3 months)

          -  Severe stable cardiac angina CCS III - IV or Unstable angina

          -  Chronic inflammation (i.e. IBD, Lupus, inflammatory arthritis, rheumatoid arthritis)
             or chronic infection (i.e. chronic diabetic foot infection)

          -  Pregnancy, lactation or child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Klempfner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center, Cardiac Rehabilitation Institute</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011 Nov 22;124(21):2338-49. doi: 10.1161/CIRCULATIONAHA.111.041418. Epub 2011 Oct 17.</citation>
    <PMID>22007077</PMID>
  </reference>
  <reference>
    <citation>Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2012 Dec;14(12):1061-72. doi: 10.1111/j.1463-1326.2012.01610.x. Epub 2012 May 17. Review.</citation>
    <PMID>22519906</PMID>
  </reference>
  <reference>
    <citation>Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010 Oct 7;363(15):1410-8. doi: 10.1056/NEJMoa1003795.</citation>
    <PMID>20925543</PMID>
  </reference>
  <reference>
    <citation>Jenny NS, Brown ER, Detrano R, Folsom AR, Saad MF, Shea S, Szklo M, Herrington DM, Jacobs DR Jr. Associations of inflammatory markers with coronary artery calcification: results from the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2010 Mar;209(1):226-9. doi: 10.1016/j.atherosclerosis.2009.08.037. Epub 2009 Aug 28.</citation>
    <PMID>19766217</PMID>
  </reference>
  <reference>
    <citation>Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010 Aug;42(9):663-9. doi: 10.1055/s-0030-1255036. Epub 2010 Jun 17.</citation>
    <PMID>20560108</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Robert Klempfner Heart Rehabilitation Institute</investigator_full_name>
    <investigator_title>Robert Klempfner MD</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>vildagliptin</keyword>
  <keyword>metformin</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>inflammation</keyword>
  <keyword>interleukin-6</keyword>
  <keyword>TNF</keyword>
  <keyword>atherothrombosis</keyword>
  <keyword>adiponectin</keyword>
  <keyword>MMP-9</keyword>
  <keyword>hs-CRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

